Progyny (NASDAQ:PGNY) Shares Gap Down – Here’s What Happened

Shares of Progyny, Inc. (NASDAQ:PGNY) gapped down prior to trading on Friday . The stock had previously closed at $30.21, but opened at $25.56. Progyny shares last traded at $27.7760, with a volume of 452,256 shares trading hands.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported adjusted earnings of $0.55 per share, above estimates ranging from $0.33 to $0.51 and up from $0.19 in the year-ago quarter. Revenue rose 5.3% year over year to $350.5 million, slightly exceeding the $348.6 million consensus estimate. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Management issued full-year 2026 EPS guidance of $2.04 to $2.10, above the roughly $1.86 analyst consensus. The outlook indicates stronger profitability than Wall Street had expected. Progyny Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: Full-year revenue guidance was maintained at approximately $1.4 billion, broadly in line with analyst expectations. The earnings presentation and call provided additional detail on the quarter and outlook, but the reported figures remain the primary catalyst for investors. Progyny 2026 Q2 Results Earnings Call Presentation
• Negative Sentiment: Third-quarter revenue guidance of $335 million to $345 million fell below the approximately $350.2 million consensus estimate, even though projected EPS of $0.50 to $0.52 exceeded the $0.47 estimate. The revenue shortfall likely raised concerns about client growth and near-term demand momentum. Progyny Reports Q2 Earnings: Key Metrics
• Negative Sentiment: The market reaction suggests investors placed greater emphasis on the below-consensus third-quarter revenue outlook and only 5.3% year-over-year quarterly revenue growth than on the earnings beat and improved full-year EPS guidance. Progyny Q2 Results and Stock Reaction

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group set a $35.00 target price on shares of Progyny in a report on Friday. Citigroup restated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. KeyCorp increased their price objective on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Citizens Jmp raised their target price on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Finally, BTIG Research boosted their target price on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Progyny Price Performance

The stock has a market cap of $2.27 billion, a PE ratio of 37.81, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. The stock’s fifty day moving average is $29.02 and its 200-day moving average is $23.40.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $350.51 million for the quarter, compared to the consensus estimate of $348.63 million. During the same period in the previous year, the firm earned $0.19 earnings per share. Progyny’s quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, sell-side analysts expect that Progyny, Inc. will post 1.19 EPS for the current fiscal year.

Progyny declared that its Board of Directors has authorized a stock repurchase program on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to repurchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Insider Activity at Progyny

In other news, EVP Allison Swartz sold 1,199 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total transaction of $29,998.98. Following the completion of the transaction, the executive vice president directly owned 83,316 shares in the company, valued at approximately $2,084,566.32. This represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the sale, the insider directly owned 59,117 shares of the company’s stock, valued at $1,512,212.86. The trade was a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,916 shares of company stock valued at $939,875 over the last 90 days. Corporate insiders own 9.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PGNY. Royal Bank of Canada raised its stake in shares of Progyny by 384.8% in the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the period. Amundi boosted its position in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares during the last quarter. Invesco Ltd. increased its holdings in Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares during the last quarter. Finally, Walleye Capital LLC raised its position in Progyny by 6.9% in the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after purchasing an additional 780 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.